IL90030A - Compositions for binding bio-affecting substances to surface membranes of bio-particles - Google Patents

Compositions for binding bio-affecting substances to surface membranes of bio-particles

Info

Publication number
IL90030A
IL90030A IL9003089A IL9003089A IL90030A IL 90030 A IL90030 A IL 90030A IL 9003089 A IL9003089 A IL 9003089A IL 9003089 A IL9003089 A IL 9003089A IL 90030 A IL90030 A IL 90030A
Authority
IL
Israel
Prior art keywords
cells
alkyl
compound
alkenyl
alkynyl
Prior art date
Application number
IL9003089A
Other languages
English (en)
Hebrew (he)
Other versions
IL90030A0 (en
Original Assignee
Zynaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynaxis Inc filed Critical Zynaxis Inc
Publication of IL90030A0 publication Critical patent/IL90030A0/xx
Publication of IL90030A publication Critical patent/IL90030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0085—Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL9003089A 1988-05-02 1989-04-19 Compositions for binding bio-affecting substances to surface membranes of bio-particles IL90030A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18919288A 1988-05-02 1988-05-02

Publications (2)

Publication Number Publication Date
IL90030A0 IL90030A0 (en) 1989-12-15
IL90030A true IL90030A (en) 1995-12-08

Family

ID=22696320

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9003089A IL90030A (en) 1988-05-02 1989-04-19 Compositions for binding bio-affecting substances to surface membranes of bio-particles

Country Status (9)

Country Link
US (2) US5667764A (fr)
EP (1) EP0430968B1 (fr)
JP (1) JP3038339B2 (fr)
AT (1) ATE145337T1 (fr)
AU (1) AU641361B2 (fr)
CA (1) CA1336272C (fr)
DE (1) DE68927479T2 (fr)
IL (1) IL90030A (fr)
WO (1) WO1989010758A1 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145337T1 (de) * 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5562894A (en) * 1991-08-09 1996-10-08 Regents Of The University Of California Amino-acyl-type and catecholamine-type contrast agents for MRI
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0643706A1 (fr) * 1991-11-27 1995-03-22 Zynaxis Inc. Composes, compositions et procedes permettant de lier des substances bio-actives aux membranes de surface de bio-particules
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
CA2472404A1 (fr) * 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combinaison de stent et d'un facteur anti-angiogenique
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
EP1118325B2 (fr) * 1993-07-29 2010-01-06 The United States of America, represented by the Secretary, Department of Health and Human Services Utilisation du Paclitaxel et ses dérivés dans la fabrication d'un médicament destiné au traitement de la resténose
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7846202B2 (en) * 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US7896914B2 (en) 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7867275B2 (en) 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
DE19539409C2 (de) * 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
US5804389A (en) * 1995-12-29 1998-09-08 Phanos Technologies, Inc. Method for detecting abnormal epithelial cell shedding
EP0881227A1 (fr) * 1996-10-22 1998-12-02 Daikin Industries, Limited Gangliosides ayant des fractions ceramide a marquage fluorescent
US6117099A (en) 1996-10-23 2000-09-12 In-Line Diagnostics Corporation System and method for noninvasive hemodynamic measurements in hemodialysis shunts
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
AU7563798A (en) * 1997-04-30 1998-11-24 Emory University Methods and compositions for administering dna to mucosal surfaces
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US8974363B2 (en) * 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20090117199A1 (en) * 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU1932900A (en) 1998-12-04 2000-06-26 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
US20050171594A1 (en) * 1998-12-31 2005-08-04 Angiotech International Ag Stent grafts with bioactive coatings
US20020065546A1 (en) * 1998-12-31 2002-05-30 Machan Lindsay S. Stent grafts with bioactive coatings
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
CA2273609A1 (fr) * 1999-06-04 2000-12-04 Resolution Pharmaceuticals Inc. Produits radiopharmaceutiques et methodes d'imagerie
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
AU2001245424B2 (en) 2000-03-03 2005-08-18 Phanos Technologies, Inc. Fluorescent membrane intercalating probes and methods for their use
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
CA2424029C (fr) 2000-09-29 2008-01-29 Cordis Corporation Dispositifs medicaux enrobes
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
WO2002080885A1 (fr) * 2001-04-03 2002-10-17 University Of Florida Detoxication et decontamination par traitement a base de nanotechnologies
US6977171B1 (en) 2001-04-03 2005-12-20 University Of Florida Detoxification and decontamination using nanotechnology therapy
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US9157875B2 (en) * 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US6761878B2 (en) * 2001-10-17 2004-07-13 Mallinckrodt, Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
US20030105300A1 (en) * 2001-10-17 2003-06-05 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
MXPA04003625A (es) 2001-10-19 2004-12-02 Sotechnika Inc Sintesis de analogos de ciclosporina.
US6723851B2 (en) 2001-10-31 2004-04-20 Quest Diagnostics Investment Incorporated Chemiluminescent compounds and use thereof
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
DK1521603T3 (da) 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
US20060134001A1 (en) * 2002-07-12 2006-06-22 Frangioni John V Conjugated infrared fluorescent substances for detection of cell death
GB0217556D0 (en) * 2002-07-30 2002-09-11 Amersham Biosciences Uk Ltd Site-specific labelling of proteins using cyanine dye reporters
CA2505576A1 (fr) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Dispositif medical extensible et procede de traitement d'occlusions totales chroniques par administration locale d'un facteur angiogenique
AU2003300022A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Silk-containing stent graft
EP1610823B1 (fr) 2003-03-28 2011-09-28 Innovational Holdings, LLC Dispositif medical implantable a gradient de concentration d'agent continuel
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050070602A1 (en) * 2003-09-30 2005-03-31 Jen-Wei Chiao Method of modulating immune response by administration of immuno-activation agent
WO2005044142A2 (fr) * 2003-11-10 2005-05-19 Angiotech International Ag Dispositifs intravasculaires et agents d'induction de fibrose
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
DE602005025911D1 (de) 2004-11-22 2011-02-24 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
AU2005234696B2 (en) * 2005-11-18 2012-02-16 Phanos Technologies, Inc. Fluorescent membrane intercalating probes and methods for their use
US20100203637A1 (en) * 2006-09-06 2010-08-12 Elena Korchagina Fluorescent cell markers
ES2530862T3 (es) 2007-02-07 2015-03-06 Cook Medical Technologies Llc Revestimientos de dispositivos médicos para liberar un agente terapéutico a diferentes velocidades
WO2009152440A1 (fr) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Conjugués médicament-ligand à petite molécule pour traitement ciblé contre le cancer
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
WO2013119877A1 (fr) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Nanosphères dérivées de virions pour l'administration sélective d'agents thérapeutiques et diagnostiques dans des cellules cancéreuses
EP3046583B1 (fr) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Conjugués de pseudo-particules virales destinés au traitement de tumeurs
EP3259862B1 (fr) * 2015-02-20 2020-05-27 Telefonaktiebolaget LM Ericsson (publ) Commande de connexions radio dans un réseau cellulaire
US10099961B2 (en) 2015-08-12 2018-10-16 United States Gypsum Company Fluorescent building product and related detection method
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
US12427208B2 (en) 2016-04-01 2025-09-30 University Of Cincinnati Iodinated phenolic lipids and methods and cosolvent systems for iodination of phenolic lipids
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
US10859505B2 (en) * 2018-01-26 2020-12-08 Gemological Institute Of America, Inc. (Gia) Fluorescence box for gemological applications

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US925445A (en) * 1907-10-25 1909-06-22 Alfred James Bartlett Boomerang.
US925429A (en) * 1908-03-13 1909-06-15 Chadeloid Chemical Co Finish-remover and process of making the same.
US2647054A (en) * 1951-02-21 1953-07-28 Du Pont Photographic emulsions containing sensitizing dyes
GB723316A (en) * 1951-06-11 1955-02-09 Frederick Charles Bersworth Substituted alkylene polyamine acetic acid compounds
FR1477402A (fr) * 1959-06-30 1967-04-21 Commercial Solvents Corp Amines et leur procédé de préparation
US3228904A (en) * 1962-05-03 1966-01-11 Goodrich Co B F Stabilization of synthetic polymers
US3352791A (en) * 1965-01-22 1967-11-14 American Cyanamid Co Generation of light by the reaction of peroxide with heterocyclic derivatives
DE1251764B (de) * 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
JPS565981B1 (fr) * 1969-03-07 1981-02-07
JPS4931895B1 (fr) * 1969-05-17 1974-08-26
US3673410A (en) * 1969-06-25 1972-06-27 John H Waite Method of examination of cell samples using a radioactively tagged dye
BE754191R (fr) * 1969-07-30 1971-02-01 American Cyanamid Co Procede de preparation d'isocyanates
US3916069A (en) * 1973-04-02 1975-10-28 Minnesota Mining & Mfg Reduced styryl/cyanine dye
US4110116A (en) * 1973-06-18 1978-08-29 Minnesota Mining And Manufacturing Company Fogged direct positive silver halide emulsion containing a cyanine dye having at least one benzoxazole or benzothiazole nucleus substituted with halogen atoms
US4074046A (en) * 1974-01-21 1978-02-14 American Cyanamid Company Process for azoles (ring closure of nitro compounds)
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4343782A (en) * 1978-04-20 1982-08-10 Shapiro Howard M Cytological assay procedure
US4232000A (en) * 1978-06-28 1980-11-04 The Procter & Gamble Company Radioactive scanning agents with stabilizer
US4232121A (en) * 1978-09-25 1980-11-04 Eastman Kodak Company Process for selecting methine dyes which inhibit cell growth
DE2962152D1 (en) * 1978-10-18 1982-03-25 Ciba Geigy Ag Substituted 1,11-diamino undecanes, processes for their preparation and their use
US4424201A (en) * 1978-11-28 1984-01-03 Rockefeller University Employment of a mereyanine dye for the detection of malignant leukocytic cells
US4352751A (en) * 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
US4400370A (en) * 1980-03-12 1983-08-23 Lawrence Kass Metachromatic dye sorption means for differential determination of leukocytes
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
EP0047470B1 (fr) * 1980-09-02 1985-04-24 Fuji Photo Film Co., Ltd. Méthode de mesure immunochimique
DE3105778A1 (de) * 1981-02-17 1982-09-02 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von trimethinfarbstoffen
US4500509A (en) * 1981-03-11 1985-02-19 Lawrence Kass Metachromatic dye sorption and fluorescent light emmisive means for differential determination of developmental stages of neutrophilic granulocytic cells and other leukocytes
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
DE3238353A1 (de) * 1982-10-15 1984-04-19 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur simultanen quantitativen bestimmung der blutzellen und reagenz hierfuer
US4555396A (en) * 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4582700A (en) * 1983-09-01 1986-04-15 Mallinckrodt, Inc. Products and processes
US4670545A (en) * 1984-05-11 1987-06-02 University Patents, Inc. Chelating agents for technetium-99M
US4714606A (en) * 1984-05-15 1987-12-22 Cytocolor Incorporated Method of staining and identifying cells and compositions thereof
US4748129A (en) * 1984-08-28 1988-05-31 Snytex (U.S.A.) Inc. Assay method employing fluorescent cell incorporative dye
US4689292A (en) * 1984-11-11 1987-08-25 Konishiroku Photo Industry Co., Ltd. Silver halide photographic radiography light-sensitive material
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4815447A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
DE3509822A1 (de) * 1985-03-19 1986-09-25 Bayer Ag, 5090 Leverkusen Aminobernsteinsaeurederivate und ihre verwendung als emulgatoren fuer polymerdispersionen
FR2601000B1 (fr) * 1986-07-03 1988-10-21 Centre Nat Rech Scient Procede de radio-iodation de gangliosides par voie enzymatique
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4859584A (en) * 1986-10-31 1989-08-22 Smithkline Beckman Corporation Cell growth rate determination by measurement of changes in cyanine dye levels in plasma membranes
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4775625A (en) * 1986-11-21 1988-10-04 The Medical College Of Wisconsin, Inc. Inactivating enveloped viruses with a merocyanine dye
FR2637895B1 (fr) * 1988-10-14 1992-11-06 Guerbet Sa Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
FI884721A7 (fi) * 1987-10-15 1989-04-16 Moskovsky Gosudarstvenny Univ Fluorijohdannnaisten käyttö varjoaineina
EP0396626A1 (fr) * 1988-01-19 1990-11-14 Board Of Regents, The University Of Texas System Glycosides, compositions liposomiques a base de ces composes et procedes d'utilisation
AU621585B2 (en) * 1988-02-03 1992-03-19 Hybritech Incorporated Improvements in or relating to modified haptens useful as imaging and therapeutic agents
ATE145337T1 (de) * 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US4906750A (en) * 1988-06-08 1990-03-06 Eastman Kodak Company Sulfoalkyl benzoxazoleinylidene butenylidene thiobarbituric acid derivatives
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
CA1341373C (fr) * 1988-06-24 2002-07-02 Roberta C. Cheng Agents chelateurs bifonctionnels macrocycliques, leurs complexes et leurs conjugues d'anticorps
IL91414A0 (en) * 1988-08-31 1990-04-29 Zynaxis Technologies Inc Reagents and methods for the determination of analytes
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (fr) * 1990-05-03 1991-11-14 Vical, Inc. Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
FR2669633B1 (fr) * 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
EP0430968A1 (fr) 1991-06-12
JPH04502755A (ja) 1992-05-21
DE68927479D1 (de) 1997-01-02
US5667764A (en) 1997-09-16
EP0430968A4 (en) 1993-10-20
IL90030A0 (en) 1989-12-15
EP0430968B1 (fr) 1996-11-20
CA1336272C (fr) 1995-07-11
AU641361B2 (en) 1993-09-23
WO1989010758A1 (fr) 1989-11-16
ATE145337T1 (de) 1996-12-15
JP3038339B2 (ja) 2000-05-08
AU3968589A (en) 1989-11-29
US5665328A (en) 1997-09-09
DE68927479T2 (de) 1997-04-03

Similar Documents

Publication Publication Date Title
US5665328A (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
JP4095847B2 (ja) バイオ作用性物質をバイオ粒子表面膜へ結合するための化合物、組成、および方法
CA1294545C (fr) Reperage des cellules in vivo
US5419894A (en) Complexing agents, complexes and complex salts
EP0248506B1 (fr) Marquage de molécules de support par les ions métalliques
US5928627A (en) Fluorescent chelates as visual tissue specific imaging agents
US7670590B2 (en) Perturbed membrane-binding compounds and methods of using the same
DE69317771T2 (de) Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate
US4363793A (en) Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues
JPH02160795A (ja) テクネチウム―９９ｍ錯体形成用キット
WO2014066733A2 (fr) Procédés et compositions pour le radiomarquage spécifique d'un site et à médiation par une enzyme de glycoprotéines
DE69332741T2 (de) Nachweis von hypoxia
DE69837038T2 (de) Tetraaza- oder n2s2-komplexanten, und deren verwendung in der radiodiagnostik oder radiotherapie
EP0096871A2 (fr) Composition pour faire une image de cellules sanguines
EP0998946A1 (fr) Composés Non-Porphyriques à application diagnostique et/ou pharmaceutique
JP2004528275A (ja) 乱れた膜に結合する化合物
US5840859A (en) (Aminostyryl)pyridinium compounds for radiolabelling cell membranes
CN1017652B (zh) 体内细胞示踪
Chopra Abbreviated name:[64 Cu] DO3A-xy-ACR Synonym: Agent Category: Compound
GB2214507A (en) 2,3-dithiosuccinic acid derivative and their use

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void